Clinical Trial: NCT05340309
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | University of Southern California |
| Information Provided By: | University of Southern California |
| Last Update Posted: | 2026-01-29 |
Study Overview
Brief Summary
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.
Official Title
Conditions
Intervention / Treatment
- Biological: Atezolizumab and Recombinant Human Hyaluronidase
- Other: Survey Administration
Other Study ID Numbers
- 2N-21-9
- NCI-2022-02425
- 2N-21-9
- P30CA014089
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | University of Southern California |
| Information Provided By: | University of Southern California |
| Last Update Posted: | 2026-01-29 |
Study Overview
Brief Summary
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.
Official Title
Conditions
Intervention / Treatment
- Biological: Atezolizumab and Recombinant Human Hyaluronidase
- Other: Survey Administration
Other Study ID Numbers
- 2N-21-9
- NCI-2022-02425
- 2N-21-9
- P30CA014089